根据 4 位华尔街分析师的预测,AddLife AB 的收入预期范围从 $2.84B 到 $2.6B
AddLife AB 的盈利质量评分是多少?
AddLife AB 的盈利质量评分为 /。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
AddLife AB 何时发布财报?
AddLife AB 的下一份财报预计在 2026-05-05 发布
AddLife AB 的预期收益是多少?
根据华尔街分析师的预测,AddLife AB 的预期收益为 $2.82B
AddLife AB 是否超出收益预期?
AddLife AB 最近的收益为 $2.73B,未达预期 预期。
关键数据
前收盘价
--
开盘价
--
当日区间
-
52周范围
-
交易量
--
平均成交量
--
股息收益率
--
每股收益(TTM)
--
市值
--
什么是 ADDLY?
AddLife AB engages in the ownership and acquisition of firms in niche segments under the healthcare sector. The company is headquartered in Stockholm, Stockholm and currently employs 2,295 full-time employees. The company went IPO on 2015-03-16. The firm markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The firm operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The firm operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.